Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
Tsao, AS; Dahlberg, SE; de Perrot, M; Fennell, DA; Friedberg, J; Gill, RR; Gomez, DR; Harpole, DH, Jr; Hassan, R; Hesdorffer, M; Hirsch, FR; Lindwasser, OW; Hmeljak, J; Kindler, HL; Korn, EL; Liu, G; Mansfield, AS; Nowak, AK; Pass, HI; Peikert, T; Rimner, A; Robinson, BWS; Adjei, AA; Rosenzweig, KE; Rusch, VW; Salgia, R; Sepesi, B; Simone, CB; Sridhara, R; Szlosarek, P; Taioli, E; Tsao, MS; Yang, H; Adusumilli, PS; Zauderer, MG; Malik, SM; Beyers, ML; Blumenthal, GM; Bueno, R; Burt, BM; Carbone, M; ,
On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network. Crown Copyright (C) 2018 Published by Elsevier Inc.